Precision Medicine in Oncology
CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Head & Neck Cancers
Immunotherapy in GU Cancers
Immunotherapy in Lung Cancer
Immunotherapy in Melanoma
Mantle Cell Lymphoma
Melanoma & Skin Cancer
Oncology Nursing News
Special Reports in Personalized Cancer Care
SELECT A TOPIC
Attend An Event
State of the Science Summit
Regional Seminar Series
Giants of Cancer Care
Precision Medicine in Oncology
<< View More Conferences
2014 ASCO Annual Meeting
Oncology Conference Multimedia
View more videos >>
Dr. Perez on a Genomic Analysis of the NCCTG N9831 Adjuvant Trastuzumab Trial
Dr. Patel on an Analysis of Olaparib and Cediranib for Ovarian Cancer
Dr. Schlumberger Draws Conclusions From the SELECT Trial in Thyroid Cancer
Oncology Conference Articles
Continuing Afatinib Beyond Progression Improves PFS in Metastatic NSCLC
Continuing EGFR inhibition beyond progression with afatinib plus paclitaxel significantly improved PFS and ORR compared with chemotherapy alone in patients with heavily pretreated metastatic NSCLC.
Pembrolizumab Induces Robust Responses in PD-L1-positive NSCLC
The anti-PD-1 humanized antibody pembrolizumab has robust antitumor activity as a first-line treatment for patients with advanced PD-L1-positive NSCLC.
Necitumumab Delivers Rare Survival Benefit in Squamous NSCLC
Adding necitumumab to standard of care with gemcitabine-cisplatin significantly improves survival compared with chemotherapy alone as first-line treatment in patients with stage IV nonâ€“small-cell lung cancer of squamous histology.
Panobinostat Combination Improves PFS in Multiple Myeloma
Combining panobinostat (LBH589) with bortezomib and dexamethasone delayed disease progression by 3.9 months over bortezomib and dexamethasone alone in patients with relapsed or relapsed and refractory multiple myeloma.
Anti-CD38 Antibody Generates Excitement in Multiple Myeloma
The CD38-specific monoclonal antibody SAR650984 demonstrated encouraging efficacy as a monotherapy and in combination with dexamethasone and lenalidomide without reaching a maximum tolerated dose in patients with heavily pretreated multiple myeloma.
Follow-up of Concurrent Immunotherapies Shows Unprecedented Survival Rate in Melanoma
Long-term follow-up results demonstrated nearly doubled median OS with the combination of ipilimumab and nivolumab compared with either agent alone.
'Smart' Alkylator TH-302 Shows Clinical Benefit in Early Multiple Myeloma Trial
The addition of the investigational hypoxia-targeted drug TH-302 to dexamethasone has demonstrated beneficial activity and a manageable adverse event profile in the treatment of patients with relapsed/refractory multiple myeloma.
Novel Rituximab Combinations Highly Effective in CLL
The novel agents idelalisib and ABT-199 in combination with rituximab have demonstrated impressive activity with manageable toxicity for patients with relapsed or refractory chronic lymphocytic leukemia.
Practice-Changing Data Revealed for Premenopausal HR+ Breast Cancer
A joint analysis of two phase III trials involving a total of 4690 premenopausal women with hormone-receptorâ€“positive (HR+) breast cancer demonstrated that adjuvant use of the aromatase inhibitor (AI), exemestane, reduced relative risk of developing subsequent invasive cancer by 28% compared with tamoxifen when both agents were combined with ovarian function suppression (OFS).
T-VEC Combinations, Monotherapy Intriguing in Unresectable Melanoma
The intratumoral injection talimogene laherparepvec demonstrated promise in combinations and utility as a monotherapy in certain subsets of patients with unresectable melanoma.
HPV-Targeting Immunotherapy Shows Early Promise in Cervical Cancer
Two patients with metastatic cervical cancer achieved durable complete responses that have so far lasted from 15 to 22 months through an adoptive T-cell therapy (ACT) targeting the human papillomavirus (HPV) in a study that researchers say supports the concept that the experimental immunotherapy approach may be beneficial in a variety of tumor types.
New Study Findings Confirm Pembrolizumab's Durable Responses in Metastatic Melanoma
The anti-PD 1 checkpoint inhibitor, pembrolizumab, continues to deliver impressive results in patients with advanced melanoma-producing long-lasting responses and improved overall survival, regardless of whether patients have been previously treated with ipilimumab.
Adjuvant Ipilimumab Reduces Risk of Recurrence in Stage III Melanoma
The immunotherapy drug ipilimumab reduced the relative risk of cancer recurrence in the adjuvant setting by 25% compared to placebo for patients with high-risk, lymph-node positive melanoma.
CO-1686 Continues to Show Promising Results in Treatment-Resistant NSCLC
The third-generation EGFR inhibitor CO-1686 continues to demonstrate promising activity in patients with nonâ€“small cell lung cancer (NSCLC) who developed resistance after prior treatment with an EGFR tyrosine kinase inhibitor (TKI).
Survival Comparable With Bevacizumab, Cetuximab in mCRC
Frontline therapy with bevacizumab (Avastin) or cetuximab (Erbitux) combined with either FOLFOX or FOLFIRI yielded a comparable survival benefit of approximately 29 months in patients with KRAS wild-type metastatic colorectal cancer
Adding Chemo to ADT Confers Dramatic Survival Gains in Prostate Cancer
In what was described as "an almost unprecedented improvement in median survival," the addition of the chemotherapy drug docetaxel to standard hormone therapy prolonged life for men with newly diagnosed metastatic, hormone-sensitive prostate cancer by nearly 14 months.
Negative ALTTO Results Reverberate for Lapatinib, Novel Clinical Trials
A dual HER2-blockade strategy that added lapatinib to trastuzumab for the adjuvant treatment of women with early breast cancer failed to demonstrate a significant improvement in DFS over the standard therapy with trastuzumab alone.
Investigational Immunotherapy Granted First Breakthrough Therapy Designation in Bladder Cancer
MPDL3280A reduced tumors in 43% of patients with previously treated PD-L1-positive metastatic bladder cancer, resulting in the first breakthrough therapy designation from the FDA for a treatment in this setting.
Ramucirumab Modestly Improves Survival in Advanced NSCLC
Adding the VEGFR-2 inhibitor ramucirumab to standard docetaxel improved overall survival by 1.4 months versus docetaxel alone in patients with advanced nonâ€“small cell lung cancer.
Targeted Therapy Combination Improves PFS in Ovarian Cancer
Combining the oral targeted agents olaparib and cediranib resulted in a near-doubling of median progression-free survival (PFS) among women with recurrent ovarian cancer in a phase II study highlighted Saturday during the 2014 American Society of Clinical Oncology (ASCO) Annual Meeting.
Ibrutinib Triples PFS, Doubles OS in Phase III CLL Trial
Treatment with single-agent ibrutinib dramatically increased PFS by nearly 80% and significantly extended OS by 57% compared with ofatumumab in patients with relapsed or refractory CLL.
Lenvatinib Likely to Become Standard in Resistant Differentiated Thyroid Cancer
Lenvatinib, a novel multityrosine kinase inhibitor, is highly effective against differentiated thyroid cancer that has become resistant to standard RAI therapy.
Study Supports Dialing Back Radiation for Some Patients With HPV-Positive Oropharyngeal Cancer
Patients with less aggressive, HPV-positive oropharyngeal cancer can be effectively treated with a lower-dose radiation regimen depending upon their response to combination induction therapy.
Goserelin Preserves Fertility, Aids Survival During Breast Cancer Chemo
Adding goserelin to chemotherapy for women with early-stage hormone receptor (HR)-negative breast cancer helps both to preserve their fertility and to prolong their survival.
Early Palliative Care for Caregivers Improves Their Wellbeing, Too
A phone-based intervention that offers practical tools to help family caregivers support their loved one with advanced cancer-as well as emphasizing the importance of maintaining a healthy lifestyle themselves-resulted in less caregiver depression and better quality of life, according to the findings of a new study presented May 30 at the 50th Annual ASCO Meeting in Chicago.
Zoledronic Acid Can Be Administered Less Frequently in Breast Cancer
The dosing frequency of zoledronic acid can be reduced by 67% without compromising efficacy and safety in women with breast cancer and bone metastases.
Reducing Pills From the Cup: Discontinuing Statins in Late-Stage Cancer Patients
For patients with less than a year to live, the discontinuation of statins may increase the median time-to-death and improve quality of life.
As Lung Cancer Screening Debate Continues, Study Projects Implementation Outcomes
In December 2013, the US Preventive Services Task Force (USPSTF) recommended that asymptomatic, high-risk individuals receive annual screening for lung cancer with low-dose computed tomography (LDCT).
Novel TKI May Provide New Treatment Option for Patients With Recurrent PVNS
The new targeted drug, PLX3397, has demonstrated responses in patients with pigmented villonodular synovitis (PVNS), a rare joint disorder.
For Premenopausal Women With ER-Positive Disease, Obesity Is a Major Risk Factor in Breast Cancer Mortality
Obesity significantly increases the risk of dying of breast cancer in premenopausal women with ER-positive early disease.
Delaying ADT Until Symptoms Appear Does Not Impact Survival, Study Suggests
A rising prostate-specific antigen after surgery or radiation therapy for prostate cancer is not enough reason, on its own, to initiate androgen-deprivation therapy.
AZD9291 Shows Robust Activity in Resistant EGFR-positive NSCLC
The highly selective EGFR inhibitor AZD9291 demonstrated an overall response rate of 64% without inducing dose-limiting toxicities in patients with metastatic NSCLC who harbor an acquired EGFR T790M resistance mutation.
Breakthrough Status in Lung Cancer, Fast Track Status in Lung Cancer, and 2019 WCLC Highlights
Small Subgroups May Hold Big Clinical Clues in Oncology
Superiority of Third-Generation EGFR TKI
Dr. Moore on Research Evaluating Repeat Exposure to PARP Inhibition in Ovarian Cancer
Key Takeaway 3: Role of Frontline I/O Still Pending
Covering Every Angle of Oncology Practice. Click a cover below, to view more.
American Journal of Managed Care
Oncology Nursing News
Physicians' Education Resource
Physician's Money Digest
Specialty Pharmacy Times
Terms & Conditions
2 Clarke Drive
Cranbury, NJ 08512
Copyright OncLive 2006-2019
Intellisphere, LLC. All Rights Reserved.